

## Advisory Board on Locally Advanced and Metastatic Urothelial Carcinoma (la/mUC): Identifying Unmet Needs and Improving **Patient Outcomes**

Dear {{customText[Dr|Prof|A/Prof|Mr|Ms]}} {{accFname}} ,{accLname}},



24 August 2024, Saturday



6.00pm - 9.10pm



Le Meridien Hotel Kuala Lumpur

| Time            | Agenda  |
|-----------------|---|
| 6.00pm - 7.00pm | Early Dinner  |
| 7.00pm - 7.05pm | Opening Remarks   |
| 7.05pm - 7.25pm | EV-301 : Enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma Dr Peter H. O'Donnell, MD University of Chicago |
| 7.25pm - 7.45pm | Q&A and discussion  |
| 7.45pm - 8.10pm | Case Sharing: Findings and Outcomes from a Real World Setting Clin Asst Prof Johan Chan National Cancer Centre Singapore  |
| 8.10pm - 8.25pm | Q&A and discussion  |
| 8.25pm - 9.05pm | Discussion: Unmet needs & Patient-centred care  |
| 9.05pm - 9.10pm | Closing Remarks   |

Active participation & discussions during all sessions are encouraged\*





Dr Peter H. O'Donnell
Oncologist
University of Chicago, Medicine, USA
Associate Professor, Department of Medicine,
Section of Hematology/Oncology
The University of Chicago



Dr Johan Chan
Consultant Oncologist
Medical Oncology,
National Cancer Centre Singapore



Dr John Low
Consultant Oncologist
Sunway Medical Centre/
Pantai Kuala Lumpur

Chairperson

Yours sincerely, {{userName}}

Adverse Events should be reported to: Astellas Pharma Malaysia Sdn Bhd. at pv.my@astellas.com

Astellas is committed to protecting your personal information and will only use it in accordance with the applicable data privacy law and our Astellas Privacy Notice. For further information on how we process and protect your personal information and how you may exercise your data protection rights, please refer to our Privacy Notice at <a href="https://www.astellas.com/my/privacy-policy">https://www.astellas.com/my/privacy-policy</a>

IMPORTANT: Your consent is voluntary, and you can withdraw it any time by clicking the unsubscribe link in any email communication. However, if you withdraw your e-marketing consent, Astellas will not be able to continue certain services, like sending you medical updates and/or marketing information about Astellas products, services, news, research and activities via e-mail.



